IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9771320 B1

PDFFull Text
Date of Patent:
Sep. 26, 2017

Filed:

Jan. 05, 2015

Carbocyclic sulfone rorγ modulators

Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Jingwu Duan, Yardley, PA (US);

T. G. Murali Dhar, Newtown, PA (US);

Bin Jiang, Bryn Mawr, PA (US);

Zhonghui Lu, King of Prussia, PA (US);

Ananta Karmakar, Bangalore, IN;

Arun Kumar Gupta, Bangalore, IN;

Carolyn A. Weigelt, Langhorne, PA (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:

Elliott Korsen

Primary Examiner:

Samantha Shterengarts

Int. Cl.
CPC ...
C07C 317/14 (2006.01); C07D 213/81 (2006.01); C07D 401/04 (2006.01); C07D 237/08 (2006.01); C07C 317/20 (2006.01); C07C 317/30 (2006.01); C07C 317/46 (2006.01); C07D 471/04 (2006.01); C07D 213/30 (2006.01); C07D 213/56 (2006.01); C07D 309/04 (2006.01); C07D 309/14 (2006.01); C07D 317/44 (2006.01); C07D 231/12 (2006.01); C07D 239/38 (2006.01); C07D 241/12 (2006.01); C07D 471/10 (2006.01); C07D 257/04 (2006.01); C07D 261/08 (2006.01); C07D 263/32 (2006.01); C07D 271/06 (2006.01); C07D 211/36 (2006.01); C07D 295/16 (2006.01); C07D 295/20 (2006.01); C07D 303/06 (2006.01); C07D 305/14 (2006.01); C07D 205/04 (2006.01); C07D 211/62 (2006.01); C07D 213/40 (2006.01); C07D 213/75 (2006.01); C07D 295/155 (2006.01); C07D 295/108 (2006.01); C07D 319/20 (2006.01); C07D 285/06 (2006.01); C07D 295/18 (2006.01); C07D 295/22 (2006.01); C07D 303/34 (2006.01); C07C 317/22 (2006.01); C07C 317/44 (2006.01); C07C 317/32 (2006.01); C07C 317/50 (2006.01); C07D 213/85 (2006.01); C07D 295/185 (2006.01);
U.S. Cl.
CPC ...
C07C 317/14 (2013.01); C07C 317/20 (2013.01); C07C 317/22 (2013.01); C07C 317/30 (2013.01); C07C 317/32 (2013.01); C07C 317/44 (2013.01); C07C 317/46 (2013.01); C07C 317/50 (2013.01); C07D 205/04 (2013.01); C07D 211/36 (2013.01); C07D 211/62 (2013.01); C07D 213/30 (2013.01); C07D 213/40 (2013.01); C07D 213/56 (2013.01); C07D 213/75 (2013.01); C07D 213/81 (2013.01); C07D 213/85 (2013.01); C07D 231/12 (2013.01); C07D 237/08 (2013.01); C07D 239/38 (2013.01); C07D 241/12 (2013.01); C07D 257/04 (2013.01); C07D 261/08 (2013.01); C07D 263/32 (2013.01); C07D 271/06 (2013.01); C07D 285/06 (2013.01); C07D 295/108 (2013.01); C07D 295/155 (2013.01); C07D 295/18 (2013.01); C07D 295/185 (2013.01); C07D 295/20 (2013.01); C07D 295/22 (2013.01); C07D 303/06 (2013.01); C07D 303/34 (2013.01); C07D 305/14 (2013.01); C07D 309/04 (2013.01); C07D 309/14 (2013.01); C07D 317/44 (2013.01); C07D 319/20 (2013.01); C07D 401/04 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01); C07C 2601/02 (2017.05); C07C 2601/04 (2017.05); C07C 2601/08 (2017.05); C07C 2601/10 (2017.05); C07C 2601/14 (2017.05); C07C 2601/16 (2017.05); C07C 2602/08 (2017.05);
Abstract

Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

Find Patent Forward Citations

Loading…